Organon (OGN) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)
Organon (OGN) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
76.51% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
131.31% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
109.43% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
178.93% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-51.68% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
27.11% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-146.62% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
14.82% |
| 10 |
Organon |
3.53 Bn |
2.41 Bn |
783.00 Mn |
-6.22% |
| Date | Value |
|---|
| Mar 31, 2026 |
-6.22% |
| Jun 30, 2024 |
270.24% |
| Mar 31, 2024 |
269.02% |
| Dec 31, 2023 |
312.62% |
| Sep 30, 2023 |
86.26% |
| Jun 30, 2023 |
95.74% |
| Mar 31, 2023 |
97.55% |
